Sandra I Coufal bought TCDA once, on Jul 2, 2018

Sandra I. Coufal, M.D., is a physician, serial entrepreneur, and venture investor who served as Co‑Founder, Director, and Scientific Advisory Board member of Tricida, Inc. (TCDA) from 2013 through 2023.( In that role she was a 10% corporate insider and a director, contributing to Tricida’s drug development strategy and its 2018 NASDAQ initial public offering.( Beyond Tricida, she has co‑founded and managed the venture firms Sibling Capital LLC and Sibling Capital Ventures LLC, helped found the scientific advisory boards of Ilypsa and Relypsa, and has long served as Biomedical Advisor to the Genomics Institute of the Novartis Research Foundation.( She currently leads Toragen, Inc. as Chief Executive Officer and serves on the boards of BioAesthetics and other life‑science ventures.(

Dr. Coufal’s earlier career was in academic and clinical internal medicine, including service as Head of the Division of Internal Medicine at the Torrey Pines site of Scripps Clinic in La Jolla, California, where she also sat on the Board of Scripps Green Hospital.( She earned her Bachelor of Science in Preprofessional Studies from the University of Notre Dame, where she was designated a Notre Dame Scholar, and her M.D. from the University of Texas Southwestern Medical School at Dallas, followed by an internship and residency in internal medicine at the same institution.(

Written by Perplexity from public sources.